Conference
Testosterone suppression: Impact of testosterone level on disease progression in advanced prostate cancer.
Abstract
46
Background: In patients with advanced prostate cancer, medical castration remains a mainstay of treatment. A testosterone level below 50 ng/dL has been previously accepted as an adequate level of androgen suppression and remains the benchmark level for clinical trials. However, there is mounting evidence that lower testosterone levels may be associated with improved clinical outcomes. We evaluated our cohort of patients …
Authors
Dason S; Tong J; Allard CB; Shayegan B
Volume
30
Pagination
pp. 46-46
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 10, 2012
DOI
10.1200/jco.2012.30.5_suppl.46
Conference proceedings
Journal of Clinical Oncology
Issue
5_suppl
ISSN
0732-183X